NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara® in Europe

BEDMINSTER, N.J.–(BUSINESSWIRE)– NPS Pharmaceuticals, Inc. (NASDAQ:NPSP – News), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara® (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism …
world drug news – Yahoo News Search Results

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us